Dissecting progressive stages of 5-fluorouracil resistance in vitro using RNA expression profiling

International Journal of Cancer

Volumn 112, Issue 2, 2004, Pages 200-212

  Schmidt, Wolfgang M ^a   Kalipciyan, Maria ^b   Dornstauder, Eva ^a   Rizovski, Blanka ^b   Steger, Guenther G ^b   Sedivy, Roland ^c   Mueller, Manfred W ^a   Mader, Robert M ^b  

^a VBC Genomics Bioscience Research GmbH   (Austria)

^b UNIVERSITY OF VIENNA   (Austria)

^c UNIVERSITY HOSPITAL INNSBRUCK   (Austria)

Author keywords

5 fluorouracil; Colon cancer; Drug resistance; Expression profiling; Microarray

Indexed keywords

ABC TRANSPORTER; ATP BINDING CASSETTE TRANSPORTER C6; COLLAGEN; DNA; FLUOROPYRIMIDINE; FLUOROURACIL; INTERCELLULAR ADHESION MOLECULE 2; KERATIN; PROFILIN; PROFILIN II; RNA; THYMIDYLATE SYNTHASE; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CANCER CELL; CELL ADHESION; CELL CYCLE; COLON CANCER; CONTROLLED STUDY; CYTOSKELETON; DISSECTION; DNA REPAIR; DOWN REGULATION; DRUG TARGETING; DRUG TRANSPORT; GENE CONTROL; GENE EXPRESSION; GENE MUTATION; HUMAN; HUMAN CELL; METABOLISM; MOLECULAR CLONING; PHENOTYPE; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; STEM CELL; UPREGULATION;

ANTIMETABOLITES, ANTINEOPLASTIC; CALCIUM-BINDING PROTEINS; CELL ADHESION; COLLAGEN; COLONIC NEOPLASMS; DOWN-REGULATION; DRUG RESISTANCE, NEOPLASM; FLUOROURACIL; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; KERATINS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PHENOTYPE; TUMOR CELLS, CULTURED; UP-REGULATION;

EID: 4544240870     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/ijc.20401     Document Type: Article

References (34)

1. Edler D, Glimelius B, Hallström M, Jakobson A, Johnston PG, Moagnusson I, Ragnhammar P, Blomgren H. Thymidylate expression in colorectal cancer: a prognostic and predictive marker of benefit from adjuvant fluorouracil-based chemotherapy. J Clin Oncol 2002; 20:1721-8.
2. Allegra CJ, Parr AL, Wold LE, Mahoney MR, Sargent DJ, Johnston P, Klein P, Behan K, O'Connell MJ, Levitt R, Kugler JW, Tirona MT, Goldberg RM. Investigation of the prognostic and predictive value of thymidylate synthase, p53, and Ki-67 in patients with locally advanced colon cancer. J Clin Oncol 2002;20:1735-43.
3. Ladner RD, Lynch FJ, Groshens S, Xiong YP, Sherrod A, Caradonna SJ, Stoehlmacher J, Lenz H-J. dUTP nucleotidohydrolase isoform expression in normal and neoplastic tissues: association with survival and response to 5-fluorouracil in colorectal cancer. Cancer Res 2000; 60:3493-503.
4. Salonga D, Danenberg KD, Johnson M, Metzger R, Groshen S, Tsao-Wei DD, Lenz H-J, Leichman CG, Leichman L, Diasio RB, Danenberg PV. Colorectal tumors responding to 5-fluorouracil have low gene expression levels of dihydropyrimidine dehydrogenase, thymidylate synthase, and thymidine phosphorylase. Clin Cancer Res 2000;6:1322-7.
5. McGall GH, Christians FC. High-density genechip oligonucleotide probe arrays. Adv Biochem Eng Biotechnol 2002;77:21-42.
6. Mader RM, Sieder AE, Braun J, Rizovski B, Kalipciyan M, Mueller MW, Jakesz R, Rainer H, Steger GG. Transcription and activity of 5-fluorouracil converting enzymes regulate fluoropyrimidine resistance in colon cancer in vitro. Biochem Pharmacol 1997;54:1233-42.
7. Sturn A, Quackenbush J, Trajanoski Z. Genesis: cluster analysis of microarray data. Bioinformatics 2002;18:207-8.
8. Liu G, Loraine AE, Shigeta R, Cline M, Cheng J, Valmeekam V, Sun S, Kulp D, Siani-Rose MA. NetAffx: Affymetrix probesets and annotations. Nucl Acids Res 2003;31:82-6.
9. Brazma A, Hingamp P, Quackenbush J, Sherlock G, Spellman P, Stoeckert C, Aach J, Ansorge W, Ball CA, Causton HC, Gaasterland T, Glenisson P, et al. Minimum information about a microarray experiment (MIAME)-toward standards for microarray data. Nat Genet 2001;29:365-71.
10. Longley DB, Harkin DP, Johnston PG. 5-fluorouracil: mechanisms of action and clinical strategies. Nat Rev Cancer 2003;3:330-8.
11. Heizmann CW, Fritz G, Schäfer BW. S100 proteins: structure, functions and pathology. Front Biosci 2002;7:1356-68.
12. Notterman DA, Alon U, Sierk AJ, Levine AJ. Transcriptional gene expression profiles of colorectal adenoma, adenocarcinoma, and normal tissue examined by oligonucleotide arrays. Cancer Res 2001;61:3124-30.
13. Pusztai L, Sotiriou C, Buchholz TA, Meric F, Symmans WF, Esteva FJ, Sahin A, Liu ET, Hortobagi GN. Molecular profiles of invasive mucinous and ductal carcinomas of the breast: a molecular case study. Cancer Gen Cytogen 2003;141:148-53.
14. De Lange R, Burtscher H, Jarsch M, Weidle UH. Identification of metastasis-associated genes by transcriptional profiling of metastatic versus nommetastatic colon cancer cell lines. Anticancer Res 2001; 21:2329-40.
15. Dong G, Loukinova E, Chen Z, Gangi L, Chanturita TI, Liu ET, Van Waes C. Molecular profiling of transformed and metastatic murine squamous carcinoma cells by differential display and cDNA microarray reveals altered expression of multiple genes related to growth, apoptosis, angiogenesis, and the NF-kB signaling pathway. Cancer Res 2001;61:4797-808.
16. Monks A, Harris E, Hose C, Connelly J, Sausville EA. Gentotoxic profiling of MCF-7 breast cancer cell line elucidates gene expression modifications underlying toxicity of the anticancer drug 2-(4-amino-3-methylphenyl)-5- fluorobenzothiazole. Mol Pharmacol 2002;63:766-72.
17. Scherf U, Ross DT, Waltham M, Smith LH, Lee JK, Tanabe L, Kohn KW, Reinhold WC, Myers TG, Andrews DT, Scudiero TA, Eisen MB, et al. A gene expression database for the molecular pharmacology of cancer. Nature Gen 2000;24:236-44.
18. Zhou Y, Gwadry FG, Reinhold WC, Miller LD, Smith LH, Scherf U, Liu ET, Kohn KW, Pommier Y, Weinstein JN. Transcriptional regulation of mitotic genes by camptothecin-induced DNA damage: microarray analysis of dose- and time-dependent effects. Cancer Res 2002;62:1688-95.
19. Anderson JM, Heindl LM, Bauman PA, Ludi CW, Dalton WS, Cress AE. Cytokeratin expression results in a drug resistant phenotype to six different chemotherapeutic agents. Clin Cancer Res 1996;2:97-105.
20. Marceau N, Loranger A, Gilbert S, Daigle N, Champetier S. Keratin-mediated resistance to stress and apoptosis in simple epithelial cells in relation to health and disease. Biochem Cell Biol 2001;79:543-55.
21. Netti PA, Berk DA, Swartz MA, Grodzinsky AJ, Jain RK. Role of extracellular matrix assembly in interstitial transport in solid tumors. Cancer Res 2000;60:2497-503.
22. Kouniavsky G, Khaikin M, Zvibel I, Zippel D, Brill S, Halpern Z, Papa M. Stromal extracellular matrix reduces chemotherapy-induced apoptosis in colon cancer cell lines. Clin Exp Metast 2002;19:55-60.
23. Ioachim E, Charchanti A, Briasoulis E, Karavasilis V, Tsanou H, Arvanitis DL, Agnantis NJ, Pavlidis N. Immunohistochemical expression of extracellular matrix components tenascin fibronectin collagen type IV and laminin in breast cancer: their prognostic value and role in tumour invasion and progression. Eur J Cancer 2002;38:2362-70.
24. Sethi T, Rintoul RC, Moore SM, MacKinnon AC, Salter D, Choo C, Chilvers ER, Dransfield I, Donelly SC, Strieter R, Haslett C. Extracellular matrix proteins protect small cell lung cancer cells against apoptosis: a mechanism for small cell lung cancer growth and drug resistance in vivo. Nat Med 1999;5:662-8.
25. Damiano JS, Cress AE, Hazlehurst LA, Shtil AA, Dalton WS. Cell adhesion mediated drug resistance: role of integrins and resistance to apoptosis in human myeloma cell lines. Blood 1999;93:1658-67.
26. L in addition to bax and p53 status. Int J Cancer 2002;98:498-504.
27. Pogany G, Timar T, Olah J, Harisi R, Polony G, Paku S, Bocsi J, Jeney A, Laurie GW. Role of the basement membrane tumor cell dormancy and cytotoxic resistance. Oncology 2001;60:274-81.
28. Rintoul RC, Sethi T. Extracellular matrix regulation of drug resistance in small-cell lung cancer. Clin Science 2002;102:417-24.
29. Takizawa K, Kamijo R, Ito D, Hatori M, Sumitani K, Nagumo M. Synergistic induction of ICAM-1 expression by cisplatin and 5-fluorouracil in a cancer cell line via a NF-κB independent pathway. Br J Cancer 1999;80:954-63.
30. 2-terminal kinase/activator protein-1 activation. Mol Pharmacol 2003;64:707-13.
31. Gupta S, Hussain T, MacLennan GT, Fu P, Patel J, Mukhtar H. Differential expression of S100A2 and S100A4 during progression of human prostate adenocarcinoma. J Clin Oncol 2003;21:106-12.
32. Daoud SS, Munson PJ, Reinhold W, Young L, Prabhu VV, Yu Q, LaRose J, Kohn KW, Weinstein JN, Pommier Y. Impact of p53 knockout and topotecan treatment on gene expression profiles in human colon carcinoma cells: a pharmacogenomic study. Cancer Res 2003;63:2782-93.
33. Huerta S, Harris DM, Jazirehi A, Bonavida B, Elashoff D, Livingston EH, Heber D. Gene expression profile of metastatic colon cancer cells resistant to cisplatin-induced apoptosis. Int J Oncol 2003;22:663-70.
34. Takahashi Y, Nagata T, Ishii Y, Ikarashi M, Ishikawa K, Asai S. Upregulation of vitamin D3 upregulated protein 1 gene in response to 5-fluorouracil in colon carcinoma SW620. Oncol Rep 2002;9:75-9.